Answers are grounded in this paper and cite their sources.
Observational study reveals minimal symptom changes after switching to generic drospirenone/ethinylestradiol in women with dysmenorrhea, indicating high tolerability and treatment continuation.
Generic formulations of drospirenone/ethinylestradiol are considered bioequivalent to their brand-name counterparts; however, some patients perceive symptom changes after switching. This study evaluated patient-reported short-term symptom changes after switching from a brand-name to a generic drospirenone/ethinylestradiol formulation in routine clinical practice. This single-center observational study included women treated for dysmenorrhea who switched from a brand-name to a generic drospirenone (3 mg)/ethinylestradiol (20 µg) formulation between October 2022 and July 2023. During the study period, 83 consecutive women switched to the generic formulation. Eighty-one women (97.6%) completed at least three consecutive treatment cycles and a study-specific, non-validated questionnaire and were included in the analysis, while two women were lost to follow-up. Six predefined symptoms were assessed by comparing symptoms experienced while using the generic formulation with those experienced while using the brand-name formulation after three consecutive treatment cycles. Participants were subsequently followed for one year. Among the 81 participants (mean age, 31.1 ± 7.5 years), the median duration of brand-name formulation use before switching was 30 treatment cycles (interquartile range, 17–55). Fifty-five women (67.9%) reported no symptom changes after switching. No statistically significant differences between improvement and worsening were observed for any of the six symptoms. All 81 participants completed the one-year follow-up; 77 (95.1%) continued the generic formulation and four (4.9%) resumed the brand-name formulation. Most women treated for dysmenorrhea reported no perceived short-term symptom changes after switching from the brand-name to the generic drospirenone/ethinylestradiol formulation, although individual variability was observed. Further prospective studies with longer follow-up using validated patient-reported outcome measures are warranted.
No takes yet. Share an insight, caveat, or question.
Yamaoka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: